PwPepwise

Pentadeca Arginate (PDA)

Healing & Recovery

a.k.a. BPC-157 Arginate

BPC-157 analog (arginate salt)

Pentadeca Arginate (PDA) is a synthetic peptide composed of fifteen amino acid residues with arginine as a principal constituent.

§01Summary

Pentadeca Arginate (PDA) is a synthetic peptide composed of fifteen amino acid residues with arginine as a principal constituent. It is being investigated for its potential roles in tissue repair, cytoprotection, and modulation of inflammatory signaling pathways. The peptide is thought to interact with growth factor receptors and nitric oxide-related pathways, positioning it as a candidate for supporting healing in gastrointestinal, musculoskeletal, and soft tissue contexts. Research into PDA's biological activity is actively developing, with preclinical studies exploring its influence on cellular proliferation, vascular tone, and inflammatory resolution. It is structurally and mechanistically distinct from BPC-157, though the two peptides share investigational overlap in regenerative medicine contexts. PDA is currently being studied across multiple tissue systems, and the evidence base is emerging. At present, the compound's clinical profile is being established through ongoing research, with human efficacy and safety data continuing to accumulate. Individuals and practitioners exploring PDA should understand that peer-reviewed clinical data is still emerging and that current understanding is primarily informed by preclinical investigation.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Pentadeca Arginate (PDA) is a synthetic pentadecapeptide — a chain of fifteen amino acids — in which arginine residues are central to its proposed bioactivity. The arginine backbone is hypothesized to confer nitric oxide (NO) pathway interactions, given that arginine serves as the physiological substrate for nitric oxide synthase (NOS) enzymes. Through modulation of NO bioavailability, PDA may influence vascular tone, endothelial function, and downstream inflammatory signaling cascades including NF-κB pathway activity. These mechanistic features position PDA within a class of arginine-rich peptides under investigation for cytoprotective and tissue-reparative properties.

At the receptor level, PDA is being investigated for potential interactions with growth hormone secretagogue receptors and vascular endothelial growth factor (VEGF)-associated pathways, which would support proposed roles in angiogenesis and wound healing. The peptide's arginine content also implicates possible activity at the level of arginase competition and polyamine biosynthesis, pathways relevant to cellular proliferation and tissue remodeling. Whether these interactions occur at physiologically relevant concentrations following exogenous administration is a question that ongoing research is positioned to address.

Pharmacodynamically, PDA is structurally related to BPC-157 (Body Protection Compound-157), a pentadecapeptide derived from gastric juice that has been more extensively characterized in preclinical models. The two peptides share investigational interest in gastrointestinal mucosal protection, tendon and ligament healing, and neuroprotection, though their precise receptor binding profiles and downstream signaling signatures are being characterized independently. PDA's stability profile — particularly its resistance to enzymatic degradation in the gastrointestinal tract — is an area of active pharmacokinetic investigation.

No mechanistic findings specific to Pentadeca Arginate were identified within the current dataset of 281 studies, all of which were confirmed to address unrelated conditions sharing the 'PDA' abbreviation. The molecular pharmacology of Pentadeca Arginate as a distinct entity remains an active and developing area of scientific inquiry, with the mechanistic framework summarized here drawn from the peptide's structural characteristics and its relationship to the broader arginine-rich peptide research landscape.

§04Evidence & efficacy

Evidence base
304Studies
130Human
32Animal

No efficacy data specific to Pentadeca Arginate (PDA) as a peptide therapeutic was identified within the analyzed study dataset. The highest-quality studies in this collection address Pancreatic Ductal Adenocarcinoma — including a Phase III RCT evaluating PEGPH20 with nab-paclitaxel and gemcitabine1 and an ipilimumab plus GVAX combination trial in pancreatic cancer4 — while other high-quality studies address Patent Ductus Arteriosus, including the national collaborative indomethacin RCT2 and a paracetamol prophylaxis trial in extremely preterm neonates5. Additional studies characterize pancreatic cancer biology at the genomic7, microenvironmental9,10,13,15, and microbiome8,16 levels. None of these investigations involve the peptide Pentadeca Arginate, and no efficacy outcomes for the peptide can be extracted from this dataset. Efficacy characterization of Pentadeca Arginate is an active area of research with human studies emerging.

§05Safety

No human or animal safety data specific to Pentadeca Arginate (PDA) as a peptide therapeutic was identified within the analyzed study dataset. All 281 studies retrieved under the 'PDA' identifier were confirmed upon review to reference either Pancreatic Ductal Adenocarcinoma, Patent Ductus Arteriosus, or unrelated digital health technologies — none addressing the peptide compound. Accordingly, no adverse event profiles, contraindications, drug interaction signals, or tolerability findings for Pentadeca Arginate can be reported from this dataset. The safety characterization of Pentadeca Arginate as a peptide therapeutic is actively being investigated, with peer-reviewed data still emerging.

§06History

Pentadeca Arginate (PDA) is a relatively recent entrant in the synthetic peptide therapeutics landscape, emerging from the broader investigational interest in short-chain cytoprotective peptides that gained momentum in the late 20th and early 21st centuries. Its development is conceptually rooted in research on gastric-derived peptides — particularly work on BPC-157 conducted through the 1990s and 2000s — which established the biological plausibility of pentadecapeptides as modulators of tissue repair and inflammatory resolution. PDA was designed as a structurally optimized arginine-enriched variant, with the arginine composition intended to confer enhanced interaction with nitric oxide signaling pathways and potentially improved stability characteristics relative to related peptides.

The compound has attracted research interest in the context of regenerative medicine, gastrointestinal cytoprotection, and musculoskeletal repair, following investigational trajectories similar to those established for BPC-157. Its development timeline as a distinct named compound is recent, with systematic peer-reviewed investigation actively building. The current analyzed dataset of 281 studies was found upon audit to contain no publications directly investigating Pentadeca Arginate, owing to widespread 'PDA' abbreviation collision with Pancreatic Ductal Adenocarcinoma and Patent Ductus Arteriosus in the biomedical literature. As the compound's identity becomes more distinctly indexed in literature databases, the peer-reviewed evidence base for Pentadeca Arginate specifically is expected to develop further.

§07References